Microbot Medical Inc. (NASDAQ:MBOT) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Analysts rate Microbot Medical “Moderate Buy” overall: Five of seven covering brokerages recommend buying, while one rates it hold and one sell. Their average 12-month price target is $5.08, though individual targets range from $2.50 to $12.00.
• Shares opened at $1.11, near the stock’s 52-week low of $0.93 and below its 52-week high of $2.85.
• The company reported quarterly earnings of a loss of $0.08 per share, matching consensus, while revenue of $0.24 million exceeded the $0.13 million estimate.

Shares of Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) have been given an average rating of "Moderate Buy" by the seven brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $5.08.

A number of research analysts have commented on the stock. UBS Group set a $2.50 target price on shares of Microbot Medical in a research report on Friday, October 23rd. HC Wainwright reaffirmed a "buy" rating and issued a $12.00 price target on shares of Microbot Medical in a report on Wednesday, October 21st. B. Riley Financial started coverage on Microbot Medical in a research report on Friday, September 11th. They set a "buy" rating and a $4.00 price target on the stock. Citizens Jmp started coverage on Microbot Medical in a report on Friday, October 23rd. They set a "market outperform" rating and a $2.50 price objective for the company. Finally, Weiss Ratings cut Microbot Medical from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, November 4th.

Microbot Medical Price Performance

NASDAQ:MBOT opened at $1.11 on Thursday. The firm has a market capitalization of $74.56 million, a price-to-earnings ratio of -4.63 and a beta of 1.07. The business has a 50 day simple moving average of $1.18 and a 200-day simple moving average of $1.81. Microbot Medical has a 1 year low of $0.93 and a 1 year high of $2.85.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The biotechnology company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million. As a group, analysts expect that Microbot Medical will post -0.30 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Microbot Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CTC Alternative Strategies Ltd. purchased a new position in Microbot Medical during the first quarter worth approximately $28,000. Private Advisor Group LLC purchased a new position in Microbot Medical during the first quarter valued at $54,000. Cetera Investment Advisers grew its position in shares of Microbot Medical by 44.7% in the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 13,099 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Microbot Medical by 1,688.1% in the first quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company's stock valued at $183,000 after purchasing an additional 71,560 shares during the period. 16.30% of the stock is owned by institutional investors and hedge funds.

About Microbot Medical

Microbot Medical Inc. NASDAQ: MBOT is a medical-device company developing robotic technologies for minimally invasive vascular procedures. Its systems are designed to help physicians remotely control guidewires and catheters during endovascular interventions, with the potential to improve procedural control and reduce clinicians' exposure to radiation. The company's primary product candidate is the LIBERTY Endovascular Robotic System, a compact, single-use robotic platform intended to support peripheral and neurovascular procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.